Clinical Trial Update: A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination Therapy [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the pharmacokinetics and pharmacodynamics of intravenously administered Pegasys (peginterferon alfa-2a) in chronic hepatitis C patients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis C, Chronic | Phase 1 | Status: COMPLETED